TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05754437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Light Therapy
Description: light-emitting diodes (LED), λ = 633 ± 10 nm; power of 100 mW/cm2, 15 minutes
Study: NCT06465563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068
Description: SHR-8068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine
Study: NCT05836324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA33890
Description: INCA33890 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA33890
Description: INCA33890 will be administered at protocol defined dose.
Study: NCT05698017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hOMSC300
Description: Human Oral Mucosa Stem Cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hOMSC300
Description: Human Oral Mucosa Stem Cells
Study: NCT06404489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation Program
Description: A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of three domains will be utilized to maximize their synergistic anabolic effect.~The duration of program will be set at 4 weeks. All activities will be performed in dedicated suites at each site, under supervision of qualified health professionals.
Study: NCT05209594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Relationships Program (HRP) for 2SLGBTQIA+ Youth
Description: The Healthy Relationships Program (HRP) for Two-Spirit, Lesbian, Gay, Bisexual, Trans, Queer, Intersex, and Asexual + (2SLGBTQIA+) Youth is a small group positive mental health promotion program for gender, sexual, and romantic minority youth. It helps build resiliency and promote well-being among 2SLGBTQIA+ youth. It affirms, validates, and celebrates sexual and gender diversity, cultivates a caring and supportive community, and helps 2SLGBTQIA+ youth develop skills and strategies that promote healthy relationships. This trauma-informed, strengths-focused program explores stressors unique to 2SLGBTQIA+ youth, including identity and expression invalidation, stigma, prejudice and discrimination, internalized oppression, coming out, safety, and microaggressions. This program includes 17 sessions, each lasting approximately 45 minutes. It may be delivered in school-based Genders and Sexualities Alliances/Gay-Straight Alliances (GSA) or 2SLGBTQIA+ youth group settings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard GSA Programming
Description: Students at comparison sites will participate in standard GSA programming, a safe space for 2SLGBTQIA+ youth and their allies to meet, develop relationships, support each other, socialize, and learn about sexuality and gender-related topics, and lobby for social change.
Study: NCT04864314

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity
Description: Participants in the Experimental group will receive a daily dose of 250 mg of TetraSOD® in a capsule during 90 days. After treatment, the group will stop consumption of TetraSOD® and a wash-out period of three months will start

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: Participants in the Control group will receive a daily dose of placebo in a capsule during 90 days. After treatment, the group will stop consumption of placebo and a wash-out period of three months will start
Study: NCT06028880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free2Be
Description: Free2Be is a manualized 13-week face-to-face group intervention for SM individuals with one pre-session and plus 12 intervention sessions. The themes of each session are: Human nature \& Relation with suffering (S1), Emotional regulation \& Multiple selves (S2), Creative hopelessness \& Values (S3), Compassionate attention (S4), Compassionate acceptance (S5), Self-criticism; Compassion \& Flows of compassion (S6), Compassionate imagination; Compassionate self (S7), Early experiences; Stigma and shame; \& Compassionate cognitive desfusion (S8), Compassionate thinking (S9), Difficult emotions: Shame \& Anger (S10), Coming out \& Compassionate behaviour (assertiveness) (S11), Positive emotions \& Preparing for the future (S2).
Study: NCT05605613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Antibody
Description: PD-1 Antibody, an investigational humanized IgG4 monoclonal antibody with high affinity and binding specificity for PD-1

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BACE
Description: Bronchial Arterial Chemoembolization
Study: NCT06477965

Intervention type: PROCEDURE
Intervention: Artery Embolization
Description: Embolic Solution are intended for use in occluding blood vessels for therapeutic or operative purposes. The embolic solution is used during an outpatient procedure, the physician will insert a small catheter onto the artery supplying the lining of the target joint or target localized pain. Tiny particles are then injected through the catheter into these arteries, reducing blood flow to the target area. This reduces the amount of inflammation associated with osteoarthritis, tendonitis, tenosynovitis or an injury, a process that can help decrease symptoms or eliminate the associated localized pain to this area. With understanding that it does not treat the underlying cartilage destruction or underlying condition causing pain but would like to determine the efficacy and validity of this treatment.
Study: NCT05605613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BACE
Description: Bronchial Arterial Chemoembolization
Study: NCT04860505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline (DOX \[200 mg\]) is an oral medication used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy
Description: Biktarvy (200mg) is an oral combination anti-HIV medication that contains the drugs tenofovir alafenamide, emtricitabine, and bictegravir.
Study: NCT06226155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TENDAI4PrEP
Description: An adapted problem-solving PrEP use intervention for HIV negative pregnant persons living with psychological distress, their partners, and antenatal care providers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced treatment as usual
Description: Includes monthly visits to the ANC plus a pamphlet of information that describes PrEP efficacy.~safety during pregnancy/postpartum, and PrEP availability at the ANC.
Study: NCT04780074

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single dose intervention with Standard product (SP)
Description: 2 capsules - 200 mg total CoQ10

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single dose intervention with Investigational product (IP1)
Description: 2 softgels - 200 mg total CoQ10

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single dose intervention with Investigational product (IP2)
Description: 2 softgels - 200 mg total CoQ10

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single dose intervention with Investigational product (IP3)
Description: 2 softgels - 200 mg total CoQ10

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single dose intervention with Investigational product (IP4)
Description: 2 capsules - 200 mg total CoQ10
Study: NCT04826406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab combined Apatinib regimen
Description: Camrelizumab 200mg iv every 2 weeks; Apatinib,250 mg/day.
Study: NCT05240794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABM-01
Description: Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Digital Control
Description: Placebo control for ABM-01
Study: NCT06303674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity with engaging cognitively
Description: This experimental condition will follow the following structure: involving 10 consecutive, 30 second-blocks of physical activity. This experimental condition will focus on aerobic metabolism. The total exercise time commitment is 10 minutes (30 seconds of working - 30 seconds of executing an engaging cognitive task, 1:1 work-to-rest ratio), plus 5 minutes of warm-ups and 5 minutes of cool-down activities. The cognitive task consists of solving various tangrams.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity without engaging cognitively
Description: This experimental condition will replicate the structure of the preceding one. Participants will engage in physical activity, guided by video observation and imitation. However, during the rest periods, they will refrain from engaging in cognitive tasks
Study: NCT06504901

Intervention type: DRUG
Intervention: Tislelizumab
Description: Tislelizumab 200mg ivd D1

Intervention type: DRUG
Intervention: Interleukin-2
Description: Interleukin 2 100IU HD,QOD d1-d14

Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 bid po, d1-d14

Intervention type: DRUG
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2 ivd, d1
Study: NCT05497115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Resilience and Recovery Program
Description: The Trauma Resilience and Recovery Program is a stepped model of care that is designed to deliver education at the bedside about mental health recovery after traumatic injury as well as risk assessment and brief intervention for high-risk patients (Step 1), foster symptom self-monitoring and continued education (Step 2), screen for PTSD and depression 30 days post-injury (Step 3), and provide a referral and warm handoff to mental health services if needed (Step 4).
Study: NCT05769816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody
Description: Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAs
Description: Once/day, 1 capsule/time, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAs
Description: Once/day, 1 capsule/time, oral
Study: NCT06510569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: U lab aligners
Description: Aligner group change the aligner every 10 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oramco bracket
Description: changing orthodontic wire every one month
Study: NCT04754191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: Cohort A will be treated with enfortumab vedotin on a 28 day cycle for up to 12 months.
Study: NCT05120570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIC- 1911
Description: 25 mg, 50 mg, or 75 mg administered twice a day from day 5 post HCT to day 45, and the dose escalation will stop once we identify the lowest biologically active and safe dose of VIC.
Study: NCT06646965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: individual dietetic counseling
Description: only the pregnant patient receives dietetic counseling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: family-based dietetic conseling
Description: the pregnant patient and her companion receive dietetic counseling
Study: NCT05529264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memory Tasks
Description: Participants will be asked to view pictures and videos presented on a computer screen and will be asked to recall the details of presented pictures or videos sometime later.
Study: NCT04874480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegavivint
Description: Given IV
Study: NCT04404985

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical AVF
Description: Surgical fistula creation is standard surgical procedures, where a small cut through the skin is made to create a channel directly between a vein and artery .~The study procedures are standard clinical practice, and not considered an experimental procedure.
Study: NCT05529264

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Memory Tasks
Description: Participants will be asked to view pictures and videos presented on a computer screen and will be asked to recall the details of presented pictures or videos sometime later.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Memory Tasks
Description: Participants will be asked to view pictures and videos presented on a computer screen and will be asked to recall the details of presented pictures or videos sometime later.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memory Tasks
Description: Participants will be asked to view pictures and videos presented on a computer screen and will be asked to recall the details of presented pictures or videos sometime later.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention/arousal tasks
Description: Participants will be asked to perform a continuous performance task, such as continuous addition of numbers. Additionally, participants may be presented with images and may be asked to rate the significance or arousal values for each image.
Study: NCT04404985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endo-vascular AVF
Description: Endovascular fistula creation is a minimally invasive procedure used to create a canal between close artery and vein at the forearm. A magnet attached to a catheter is passed over a guidewire into the artery while another magnet passed over the guidewire into the vein. The two magnets are aligned close to each other, then the radiofrequency electrode is released from the venous catheter and energized for 2 seconds, creating a channel between the vein and the artery.
Study: NCT06511596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BR-AC
Description: BR-AC is an amnion layer, intermediate layer, and chorion layer placental membrane processed together with no separation of the layers. BR-AC is manufactured by BioStem Technologies, Inc. and is processed by the bioREtain method which, briefly, includes initial disinfection, processing with isotonic solutions, dehydration at 37-40°C and electron beam sterilization.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Standard of care is defined as:~* Debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer, a foam pad, alginate or hydrofiber dressing for moderately draining wounds, a secondary retention bandage, and~* An off-loading device.
Study: NCT05423340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette Flavor
Description: Participants use an electronic nicotine delivery system with an assigned tobacco-flavored e-liquid
Study: NCT05529264

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention/arousal tasks
Description: Participants will be asked to perform a continuous performance task, such as continuous addition of numbers. Additionally, participants may be presented with images and may be asked to rate the significance or arousal values for each image.
Study: NCT04630899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active joint mobilization
Description: The participants bend his knees in a prone position. The physical therapist holds the medial malleolus with one hand and the lateral malleolus with the other. At the same time, the physical therapist touches the participant's soles to the sternum area and presses them in the dorsal direction. At this time, medial malleolus glides anterior and lateral malleolus glides posterior. The first procedure is to passively recognize movement. The second procedure is accompanied by active movement of the participant.
Study: NCT05529264

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention/arousal tasks
Description: Participants will be asked to perform a continuous performance task, such as continuous addition of numbers. Additionally, participants may be presented with images and may be asked to rate the significance or arousal values for each image.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention/arousal tasks
Description: Participants will be asked to perform a continuous performance task, such as continuous addition of numbers. Additionally, participants may be presented with images and may be asked to rate the significance or arousal values for each image.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Language tasks
Description: Participants will be asked to view pictures of actions or things and will be asked to name them. Participants may also be asked to read words or passages.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Language tasks
Description: Participants will be asked to view pictures of actions or things and will be asked to name them. Participants may also be asked to read words or passages.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Language tasks
Description: Participants will be asked to view pictures of actions or things and will be asked to name them. Participants may also be asked to read words or passages.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Language tasks
Description: Participants will be asked to view pictures of actions or things and will be asked to name them. Participants may also be asked to read words or passages.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visuospatial tasks
Description: Participants will be asked to copy 3 dimensional designs or make judgements of angle size.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visuospatial tasks
Description: Participants will be asked to copy 3 dimensional designs or make judgements of angle size.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visuospatial tasks
Description: Participants will be asked to copy 3 dimensional designs or make judgements of angle size.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visuospatial tasks
Description: Participants will be asked to copy 3 dimensional designs or make judgements of angle size.
Study: NCT05423340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette Flavor
Description: Participants use an electronic nicotine delivery system with an assigned tobacco-flavored e-liquid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Free Nicotine Pouch
Description: participants will use tobacco free oral nicotine pouches
Study: NCT06429761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: IV infusion
Study: NCT05986565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families Moving Forward (FMF) Teacher adapted training
Description: The FMF Connect Teacher Companion website is designed to offer teachers evidence-based education about FASD and strategies to support students with FASD. It is adapted from the FMF Program and FMF Connect, evidence based interventions to support caregivers of children with FASD. The FMF Program and FMF Connect aim to improve caregivers' efficacy and satisfaction as a parent, efficacy, attributions for their child's behavior, and the parent-child relationship.
Study: NCT06504901

Intervention type: DRUG
Intervention: Neupogen
Description: rhG-CSF 5mcg/kg HD, QD d1-d14
Study: NCT06245135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIME at Home
Description: Sessions involve a 15-minute pre-video safety check and social time; streaming a 1-hour pre-recorded exercise video; and a 15-minute post-video social time. Two trained facilitators run each class, with a maximum group size of 10 people.~The 1-hour exercise videos include a seated warm-up and cooldown, and 40 minutes of functional, self-paced exercises. In the video, 2 healthcare professionals demonstrate a lower and higher difficulty level of each exercise. The program starts with a level 1 video and switches to a level 2 video midway.~A registered healthcare professional, called the healthcare partner, visits select classes and serves as a resource to participants and facilitators.
Study: NCT06166355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification Training
Description: Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions and five sessions of Attentional Bias Modification Training.
Study: NCT06778330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin (DAPA)
Description: Control group: receive dapagliflozin in addition to standard therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin (DAPA)
Description: Control group: receive dapagliflozin in addition to standard therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Test group: receive combination therapy of dapagliflozin and a small dose of sildenafil(25mg/day) in addition to standard therapy
Study: NCT06166355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-based body exposure
Description: Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-based body exposure
Description: Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: Usual cognitive-behavioral treatment (CBT) sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Usual cognitive-behavioral treatment (CBT) sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Usual cognitive-behavioral treatment (CBT) sessions.